Osimertinib
Medication
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Wikipedia
AHFS/Drugs.com: Monograph
ATC code: L01EB04 (WHO)
Elimination half-life: 48 hours
License data: US DailyMed: Osimertinib
Other names: AZD9291, mereletinib, osimertinib mesilate (JAN JP), osimertinib mesylate (USAN US)
Pregnancy category: AU: D
People also ask
Is osimertinib considered chemotherapy?
What type of drug is osimertinib?
What is the life expectancy of someone on osimertinib?
What is the average survival of osimertinib patients?
Learn about TAGRISSO® (osimertinib), a targeted treatment option for people with certain types of EGFR+ non-small cell lung cancer (NSCLC).
Nov 15, 2022 · Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer ...
Jan 26, 2023 · Osimertinib is a type of targeted cancer drug. It is a treatment for non small cell lung cancer (NSCLC). Find out about how you have it, ...
osimertinib decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, ...
Jul 5, 2023 · Highly anticipated results from a large study of people with early-stage lung cancer are generating praise, and some controversy, ...
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations.
Learn about TAGRISSO® (osimertinib), a targeted therapy for resectable EGFRm non-small cell lung cancer (NSCLC) and the first-line treatment of metastatic ...
Dec 12, 2019 · The cancer drug osimertinib (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations, updated results from ...
Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 ...
HCPs: Read About The Data On The TAGRISSO Physician Site. View New FLAURA2 Clinical Trial. Visit The HCP Site To Learn...